Systematic Review of First-Line Chemotherapy for Newly Diagnosed Postoperative Patients with Stage II, III, or IV Epithelial Ovarian Cancer

Covens, Allan; Carey, Mark; Bryson, Peter; Verma, Shailendra; Fung, Michael Fung Kee; Johnston, Mary

doi:10.1006/gyno.2001.6552

Cited by 133 publications

(89 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…At advanced stages of the disease (III and IV), current therapeutic strategies become increasingly ineffective (2). Derivatives of cisplatin (CDDP: cis-diamminedichloroplatinum) are the first line treatments for OVCA, often administered together with paclitaxel (3). CDDP is genotoxic in vivo and functions by crosslinking DNA, resulting in cell-cycle arrest and ultimately triggering apoptosis.…”

mentioning

confidence: 99%

Piceatannol Enhances Cisplatin Sensitivity in Ovarian Cancer via Modulation of p53, X-linked Inhibitor of Apoptosis Protein (XIAP), and Mitochondrial Fission

Farrand

Byun

Kim

et al. 2013

Journal of Biological Chemistry

View full text Add to dashboard Cite

Background: Chemotherapeutic sensitivity in ovarian cancer is dependent on effective apoptosis signaling. Results: Piceatannol enhances cisplatin sensitivity by modulating p53, XIAP (X-linked inhibitor of apoptosis protein), and mitochondrial fission in vitro and in vivo. Conclusion: Piceatannol is a potent enhancer of cisplatin-induced apoptosis. Significance: Piceatannol exhibits potential for clinical development for the treatment of ovarian cancer.

show abstract

mentioning

confidence: 99%

Piceatannol Enhances Cisplatin Sensitivity in Ovarian Cancer via Modulation of p53, X-linked Inhibitor of Apoptosis Protein (XIAP), and Mitochondrial Fission

Farrand

Byun

Kim

et al. 2013

Journal of Biological Chemistry

View full text Add to dashboard Cite

show abstract

“…First, as noted above, the neoplasm is highly chemo-sensitive, suggesting the malignant cell population may be a good model to test a variety of novel agents, both cytotoxic and cytostatic [1,2,3,4]. …”

Section: Unique Features Of Ovarian Cancer Relevant To the Concept Ofmentioning

confidence: 99%

“…Ovarian cancer is recognized to be one of the most chemotherapy-sensitive malignancies, with 70–80% of newly diagnosed patients being anticipated to exhibit a response to primary platinum plus taxane chemotherapy [1,2,3]. Despite this fact, the majority of women who present with advanced ovarian cancer will experience recurrence and ultimately die of complications associated with progressive disease [1,2,3,4].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Promise and Perils of ‘Targeted Therapy’ of Advanced Ovarian Cancer

Markman

2008

Oncology

View full text Add to dashboard Cite

For several reasons, ovarian cancer is an excellent malignancy to consider the use of ‘targeted’ therapeutic strategies. However, to date, despite considerable effort, there remains limited evidence that such approaches are clinically relevant in the malignancy. The one important exception is the delivery of anti-angiogenic anti-neoplastic agents, which actually appear to be more biologically active as single drugs in ovarian cancer than in other solid tumors where they have been examined. It is anticipated that future trials of ‘targeted’ therapy in ovarian cancer will focus on molecular targets of documented relevance in the malignancy.

show abstract

“…12,13 Chemotherapy using a paclitaxel-based regimen is now commonly used for the treatment of postoperative ovarian cancer patients. 14,15 In our study, we investigated AKAP3 mRNA expression in normal ovary and ovarian cancer, semiquantitatively using capillary electrophoresis on a microtip. A previous study showed that AKAP3 belonged to sperm proteins and the mRNA expression was observed only in the testis in normal adult tissues.…”

mentioning

confidence: 99%

A‐kinase anchoring protein 3 messenger RNA expression in ovarian cancer and its implication on prognosis

Hasegawa

Ono

Matsushita

et al. 2003

Intl Journal of Cancer

View full text Add to dashboard Cite

A-kinase anchoring protein 3 (AKAP3) is a sperm protein and its expression appears to be restricted to the testis in normal adult tissues. We investigated AKAP3 mRNA expression in 20 normal ovaries and 54 ovarian cancers of different histological types, grades and stages by reverse transcriptionpolymerase chain reaction (RT-PCR). The PCR products were analyzed by conventional agarose gel electrophoresis and capillary electrophoresis on a microtip device to determine the expression semiquantitatively. Little or no expression was observed in the 20 normal ovarian specimens. High AKAP3 mRNA expression was observed in 15 ovarian cancer specimens (28 %). Ovarian cancer represents the fifth leading cause of death from cancers in women, and the first in gynecological malignancies. 1 Because of difficulties in detection, diagnosis and treatment, the overall survival rate of ovarian cancer patients is still poor. 2,3 It is therefore necessary to overcome these difficulties. Since the discovery of human tumor antigens recognized by T-lymphocytes, 4 immunotherapy has received particular attention as one of the new modalities for cancer therapy. 5 Cancer/testis (CT) antigens, which express only in the testis in normal adult tissues and a variety of cancers, would be potential targets for human cancer vaccination. 6 There are now more than 14 genes or gene families coding for CT antigens, 6,7 e.g., MAGE, SSX, NY-ESO-1/LAGE, SCP-1 and OY-TES-1.A-kinase anchoring proteins (AKAPs) are a group of structurally diverse proteins that bind to the regulatory subunit of protein kinase A (PKA). They localize in discrete sites in a cell and enable PKA to be exposed to cAMP efficiently. 8 Recently, it has been demonstrated that AKAP-mediated PKA activation inhibited cell growth in the muscle 9 and T lymphocytes. 10,11 Paclitaxel, docetaxel and vincristine, which were shown to damage microtubules, also activate PKA and induce hyperphosphorylation of Bcl-2, cause growth arrest and apoptosis. 12,13 Chemotherapy using a paclitaxel-based regimen is now commonly used for the treatment of postoperative ovarian cancer patients. 14,15 In our study, we investigated AKAP3 mRNA expression in normal ovary and ovarian cancer, semiquantitatively using capillary electrophoresis on a microtip. A previous study showed that AKAP3 belonged to sperm proteins and the mRNA expression was observed only in the testis in normal adult tissues. 16 We showed that high AKAP3 mRNA expression was observed in ovarian cancer and the expression was correlated to the histological grade and clinical stage of the tumor. The expression in the normal ovary was only marginal. Thus, AKAP3 appeared to be a cancer/testis (CT) antigen. Furthermore, we investigated the relationship between AKAP3 mRNA expression and prognosis. We showed that AKAP3 mRNA expression was an independent and favorable prognostic factor in patients with poorly differentiated ovarian cancer. MATERIAL AND METHODS Patients and specimensFifty-four patients were investigated in our study with a median age of 54 ...

show abstract

Systematic Review of First-Line Chemotherapy for Newly Diagnosed Postoperative Patients with Stage II, III, or IV Epithelial Ovarian Cancer

Cited by 133 publications

References 27 publications

Piceatannol Enhances Cisplatin Sensitivity in Ovarian Cancer via Modulation of p53, X-linked Inhibitor of Apoptosis Protein (XIAP), and Mitochondrial Fission

Piceatannol Enhances Cisplatin Sensitivity in Ovarian Cancer via Modulation of p53, X-linked Inhibitor of Apoptosis Protein (XIAP), and Mitochondrial Fission

The Promise and Perils of ‘Targeted Therapy’ of Advanced Ovarian Cancer

A‐kinase anchoring protein 3 messenger RNA expression in ovarian cancer and its implication on prognosis

Contact Info

Product

Resources

About